Article Text

PDF
OP0030 Inequity in biologic dmard prescription for spa across the globe. results from the asas comospa study
  1. E Nikiphorou1,
  2. D van der Heijde2,
  3. S Norton1,
  4. R Landewé3,
  5. A Moltό4,
  6. M Dougados4,
  7. F van den Bosch5,
  8. S Ramiro2
  1. 1KCL, London, United Kingdom
  2. 2LUMC, Leiden
  3. 3ARC, Amsterdam, Netherlands
  4. 4Paris Descartes University, Paris, France
  5. 5Ghent University Hospital, Ghent, Belgium

Abstract

Background The value of biologic DMARDs (bDMARDs) in SpA is well recognized but global access to these treatments can be limited due to high cost and other factors.

Objectives This study explores variation in the use of bDMARDs in SpA across countries and to what extent socio-economic (SE) factors may explain variation.

Methods Patients fulfilling the ASAS SpA criteria in the multi-national, cross-sectional ASAS COMOSPA study were studied. Multi-level logistic regression models with random intercept for country were constructed with current use of bDMARDs as the dependent variable. Contribution of socio-economic factors using country health expenditures and gross domestic product (GDP) (all low vs medium/high tertiles) as independent country-level factors, was explored in models adjusted for socio-demographic as well as clinical variables known to determine bDMARD-use in SpA.

Results In total, 3370 patients from 22 countries were included (mean [SD] age 43 [14] years; 66% male; 88% axial disease). Across countries, 1275 (38%) were bDMARD users. Crude mean bDMARD-use varied between 5% (China) to 74% (Belgium). After adjustment for relevant socio-demographic and clinical variables, important variation in bDMARD-use across countries remained (Figure, p<0.001). Country-level socio-economic factors, specifically higher health expenditures were related to higher bDMARD uptake (Table), though not meeting statistical significance (OR 1.91; 95% CI 0.93,3.92). Similar findings were found with country GDP (OR 1.72;95% CI 0.83,3.57).

Conclusions There remains important residual variation across countries in bDMARD uptake of patients with SpA followed in specialized SpA centers. This is despite adjustment of well-known factors for bDMARD use such as clinical and country-level socio-economic factors.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.